ReviewDiabetes technology & therapeutics2024
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes.
Review in Diabetes technology & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Continuous Glucose Monitoring in Glycogen Storage Diseases: A Systematic Review of Clinical Utility, Accuracy and Patient Outcomes.Endocrinology, diabetes & metabolism · 2026Pooled it
- [Diabetes technology (Update 2026)].Wiener klinische Wochenschrift · 2026Guideline
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets.Hormone research in paediatrics · 2024Guideline
- Relationship between participant-reported outcomes, residual beta cell function and metabolic parameters in youth with newly diagnosed type 1 diabetes.Diabetologia · 2026Trial
- Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial.Diabetes care · 2026Trial
- Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery.Diabetes, obesity & metabolism · 2025Trial
- Ultra rapid lispro improves postprandial glucose control versus lispro in combination with basal insulin: a study based on CGM in type 2 diabetes in China.Frontiers in endocrinology · 2024Trial
- Association of Time in Range and Time in Tight Range With Cardiovascular Risk Factor Exposure in Youth With Type 1 Diabetes: A Cross-Sectional Analysis on LDL Cholesterol and Blood Pressure Data From the SWEET International Database.Diabetes, obesity & metabolism · 2026Article
- Impact of Glycemic Trajectory and Variability on Ischemic Stroke Prognosis and Exploration of Its Mechanisms: A Comprehensive Review.Healthcare (Basel, Switzerland) · 2026Review
- The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review.JMIR diabetes · 2026Review
- Glycemic Variability Bridges Time in Range and Time in Tight Range: A Unified Equation for Both Type 1 and Type 2 Diabetes Based on Large-Scale Continuous Glucose Monitoring Data.Diabetes, obesity & metabolism · 2026Article
- Nanostructured electrode materials and flexible-substrate engineering for wearable multi-analyte biosensors in diabetes monitoring and personalized care: a comprehensive review.Journal of materials science. Materials in medicine · 2026Review
- Degradation-as-ignal: a digital-twin framework for disposable optical glucose sensing with lead-free perovskite-inspired films.RSC advances · 2026Article
- Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real-time continuous glucose monitoring and alert functionality.Journal of diabetes investigation · 2026Article
- Advances in insulin pump systems lead to stepwise improvements in treatment satisfaction in people with type 1 diabetes: A single-center retrospective study.Journal of diabetes investigation · 2026Article
- The Expanding Role of Continuous Glucose Monitoring in the Management and Prevention of Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Insulin delivery characteristics and glycemic control in older adults with type 1 diabetes using the Minimed™ 780G system: a real-world analysis.Frontiers in endocrinology · 2026Article
- Editorial: Advancing pediatric type 1 diabetes management: metrics, technologies, and prevention of complications.Frontiers in endocrinology · 2026Article
- Continuous glucose monitoring (CGM) systems in Poland, Europe, and beyond in 2025: principles, available technologies, and future perspectives.Archives of medical science : AMS · 2026Article
- Glycemic control, including Time in Tight Range (TITR) evaluation, in children with type 1 diabetes treated with the MiniMed 780G system: a 3-year prospective, observational, two-center study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing use of continuous glucose monitoring (CGM) has been supported by expert consensus and clinical guidelines on glycemic management in diabetes with time in range (TIR 70-180 mg/dL) representing a key CGM-derived glucose metric. Time in tight range (TITR) has also been proposed for clinical use, spanning largely normal glucose levels of 70-140 mg/dL. However, keeping such narrow glucose ranges can be challenging, and understanding the factors modulating TITR can help achieve these tight glycemic targets. Our real-life study aimed to evaluate the relationship between average glucose (AG) and TIR/TITR in a large cohort (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.